Login to Your Account



Pharma: Other News To Note


Tuesday, February 7, 2012
• Merck & Co. Inc., of Whitehouse Station, N.J., said it plans to file a new drug application for Suvorexant, its orexin receptor antagonist, in insomnia this year based on results from two pivotal Phase III trials.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription